How to Get Selank: What Each Route Costs per Milligram

Friction here means what the route costs you in time, money and uncertainty before it produces anything. The final column is the honest answer to whether a rate can be computed at the end of it.

Nothing about that ranking is a recommendation. It is a description of where the friction sits, and the friction is concentrated at the top precisely because the top rows are the ones people assume exist.

Start with the ceiling, because it saves an appointment. There is no FDA-approved drug product containing Selank. Not for anxiety, not for cognition, not for anything, at any dose or route. You can confirm it in about thirty seconds in the Drugs@FDA database by searching the active ingredient and finding nothing.

Russian registration is real and is regularly quoted as if it settled the question. It does not transfer. A marketing authorisation issued by another country's regulator has no legal effect in the US, creates no NDC, and gives a physician nothing to write on a prescription pad. Reporting that Selank is registered in Russia as an anxiolytic is accurate; treating that registration as evidence of efficacy by the standards FDA applies is not, and this site is not going to do it.

The practical consequence is narrow and absolute: there is no medical route in the US that ends with a pharmacist handing over Selank. Every remaining row on the table is a way of buying a substance rather than a way of being prescribed a medicine. The same structure applies to compounds far further along in development. Our retatrutide prescription page covers a molecule deep in phase 3 trials that is equally unobtainable through a pharmacy, and for exactly the same reason.

The next rung down is the one most articles get wrong. A 503A compounding pharmacy may work with a bulk drug substance only if it has an applicable USP monograph, is a component of an FDA-approved drug, or appears on FDA's list of bulk drug substances for use in compounding. Selank satisfies none of the three.

The detail worth carrying away is what the record actually says. FDA names the substance Selank acetate (TP-7). It was nominated for that list, and the nomination was withdrawn. It sits on the safety-risks page under substances nominated but withdrawn, and it appears in no category of the 503A list, updated 14 May 2026. It is not Category 1, not Category 2, not Category 3.

That distinction is not pedantry. Category 2 is the list of substances FDA identified as raising significant safety risks, and it currently holds six: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. Selank is not one of them, and pages saying otherwise are repeating something that was never true. Being unlisted is not permission. It leaves a compounder with no defensible basis to work with the substance at all, which is why this route ends where it does, and our Selank legal position page takes the categories apart in full.

Compare a compound that did land in Category 1: our NAD+ local supply page describes an entire clinic channel built on non-enforcement pending evaluation, with chairs, sessions and published service menus. Selank has no equivalent. Wellness clinics and nootropic shops that advertise it are generally selling a consumer spray from a shelf rather than compounding anything.

Overseas sellers publish the lowest per-vial figures in this market. Per vial is the wrong unit, and four costs live outside it.

• Carriage. On a single 10 mg vial international shipping can approach or exceed the vial price, which alone can double the rate per milligram.
• Duty and brokerage. Both depend on declared value and description, neither of which you control.
• Time. Lyophilised powder is forgiving about transit, far more so than a solution, but weeks in a distribution centre are still weeks in unknown conditions.
• Total loss. A seized parcel has no return path, and a card issuer is unlikely to reverse a charge for a research chemical.

The documentation failure is quieter and worse. A certificate hosted as a single undated PDF, or emailed on request, cannot be matched to the lot code on the vial that arrived. Once that link is broken, purity, identity and measured quantity all become claims about somebody else's material, and there is no way to detect the break from the outside. Cost per milligram computed on a mass you cannot verify is arithmetic performed on a rumour.

Every route above has a hidden cost that no checkout displays, and FDA has described it in writing. On the compounding safety-risks page it states that compounded drugs containing selank acetate may pose a risk for immunogenicity for certain routes of administration, due to the potential for aggregation and peptide-related impurities, and that it lacks important information regarding any safety issues raised by selank acetate administered to humans.

Aggregation is peptide molecules clumping together. Peptide-related impurities are the truncated and modified sequences synthesis leaves behind. Both are invisible in the vial and both are measurable on paper, which is what makes the concern actionable rather than atmospheric. Purity by HPLC addresses part of it. Endotoxin testing by LAL addresses the contamination question that purity cannot see, and a microbial screen addresses a third question that endotoxin testing does not answer.

On the listing costed here, the evidence is lot-dependent, and that is the single most useful thing a buyer can know about this compound.

Match the code on the vial to the certificate that covers it. A supplier that published a full panel for one batch has not published it for yours. The sterility row also carries its own limit, stated on the report itself: it describes the method as a preliminary assessment suitable for quality control, and says full compendial testing may be required for regulatory compliance. The same discipline is the whole content of our BPC-157 acquisition guide, where the purchasing situation is identical: a research vial, no prescription route, and a certificate that has to be read rather than trusted.

Almost everyone searching where to get Selank ends at the last row of the table: a domestic research supplier, a sealed 10 mg vial, research-use labelling, and no medical framing anywhere in the transaction. That is worth saying plainly rather than implying it after four hundred words of alternatives.

What arrives is dry powder, and the numbers change unit at that point. Laboratory handling arithmetic only, with no human application implied by anything below.

Volume changes the resolution of the barrel and changes nothing about the price. Half a milligram costs $1.19 at the code rate whether it sits in five units or fifty. One correction to that arithmetic, though: if your vial holds the 12.29 mg the February certificate measured, then 2 mL gives 6.15 mg/mL rather than 5, and a draw computed from the label is about 23% heavier than the label maths predicts. That is a laboratory handling point, and it is the strongest practical argument for reading your own lot's document.

The Selank calculator runs any volume you enter, our reconstitution guide covers the handling, and the Selank price page divides the purchase every way that changes a decision.